IDEAYA Biosciences, Inc. (IDYA) has been beaten down lately with too much selling pressure. While the stock has lost 8.6% ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Oppenheimer lowered the firm’s price target on Ideaya Biosciences (IDYA) to $40 from $53 and keeps an Outperform rating on the shares after the ...

In a challenging year for biotech firms, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached a 52-week low, touching down at $21.02. According to InvestingPro data, the company maintains strong ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced financial results for the quarter and full ...

IDEAYA BIOSCIENCES ($IDYA) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of -$1.49 per share, missing estimates of -$0. ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research ...

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...